We hypothesised that ROTEM® (Basel, Switzerland) INTEM® (ROTEM, Basel, Switzerland) clotting time (CT) would have good agreement with activated partial thromboplastin time (aPTT) in determining whether a dose adjustment should be made to the unfractionated heparin (UFH) infusion in patients on extracorporeal membrane oxygenation. All patients treated with extracorporeal membrane oxygenation over a five-year period were included for data analysis. Retrospective analysis was performed of prospectively collected data points, wherein aPTT, activated CT and ROTEM was performed simultaneously to monitor UFH-based anticoagulation. Two hundred data points were available for analysis. Turnaround time was shortest for activated CT followed by ROTEM and aPTT. Despite achieving therapeutic aPTT targets, the majority (>50%) of INTEM CT results were within normal limits. The aPTT and INTEM CT results correlated weakly (r=0.31, 95% confidence interval [0.17, 0.43]) and there was no agreement between the directional changes of aPTT and INTEM CT results on successive days (χ2 = 2.33, P=0.17). Due to relative insensitivity, INTEM CT-guided UFH titration was estimated to result in a 289% increase in incidence of up-titration, over aPTT-guided titration. The INTEM CT results (r=0.36, 95% confidence interval [0.23, 0.48]) correlated weakly with UFH infusion rates. The UFH infusion rate only explained 13% variability in INTEM CT values. While haemorrhagic complications were frequent, no major clotting complications were encountered. Our results demonstrated that aPTT and INTEM CT do not provide equivalent information to guide UFH infusion rate titration during extracorporeal membrane oxygenation. Our study suggests caution regarding the use of ROTEM for guiding UFH-based anticoagulation as it may lead to excessive UFH exposure.
Critically ill patients treated with extracorporeal membrane oxygenation (ECMO) are at high risk of thrombotic complications from the procoagulant effect of prolonged exposure of blood to the artificial surface of the ECMO circuit 1, 2 . Systemic anticoagulation, usually with unfractionated heparin (UFH) by intravenous infusion, is thus an integral part of ECMO [1] [2] [3] . However, the prolonged exposure of critically ill patients to heparin predisposes them to haemorrhagic complications, which are the primary indication for premature discontinuation of ECMO 4, 5 . Maintenance of an optimal balance between the risks of thrombosis and haemorrhage, with monitoring of the patient's haemostatic status and careful titration of the UFH infusion, is thus paramount.
There are currently no international recommendations for the optimal dosing of UFH for ECMO 2, 3, 6, 7 . There is also no consensus as to the preferred monitoring test [1] [2] [3] 8 . The majority of ECMO centres use a clot formation-based test, either the activated partial thromboplastin time (aPTT) or the activated clotting time (ACT) to guide adjustment of heparin dosing [1] [2] [3] . Both of these tests have been shown to have poor correlation with heparin activity, besides certain other limitations [1] [2] [3] [9] [10] [11] [12] . More specific assays of heparin activity such as chromogenic anti-Xa activity have been advocated, but have not been widely adopted for cost and practicality reasons 1, 8, 12 .
More recently, the thromboelastography (TEG®) test, which is performed on whole blood, has been introduced as a global assay of haemostatic function, with the additional advantage of rapid point-of-care applicability 1,2 . However, use of thromboelastography for anticoagulation during ECMO is limited to anecdotal reports 1, 13, 14 . Rotational thromboelastometry (ROTEM®) (Pentapharm GmbH, Munich, Germany) is a technical refinement of thromboelastography with better reproducibility and less variability, which can provide differential assays of the intrinsic and extrinsic haemostatic pathways through a choice of activating reagents 2, 15 . One such assay, the INTEM® assay (ROTEM, Basel, Switzerland), is used to assess the intrinsic pathway of coagulation and may thus have value in monitoring UFH therapy. Use of ROTEM has been described in numerous other clinical settings [15] [16] [17] [18] , but there is a dearth of evidence regarding its use in ECMO in the intensive care setting 19 .
The purpose of our study was to compare aPTT, ACT and ROTEM tests in patients on ECMO. We hypothesised that ROTEM INTEM will have good agreement with aPTT in determining whether a dose adjustment should be made to the UFH infusion.
Methods
This retrospective study was conducted in the mixed medical and surgical ICU of a university teaching hospital. The study was approved by the Southern Adelaide Clinical Human Research Ethics Committee (HREC EC00188). The requirement for written informed consent was waived.
Patients and treatment
All patients treated with ECMO over a five-year period (December 2009 to September 2014) were included for data analysis. All patients were managed according to the institutional ECMO protocol, which specifies management of anticoagulation, circuit monitoring and safety checks. The ECMO circuit included a centrifugal pump (Maquet ® [Rastatt, Germany] Rotaflow centrifugal pump, drive and console), heater unit (Maquet Heater Unit HU35), gas blender (Sechrist ® , Anaheim, CA, USA), and hollow-fibre polymethylpentene oxygenator (Maquet Quadrox-D) and heparin-bonded circuit tubing (Bioline®, Eveleigh, New South Wales). Cannulation for ECMO was performed percutaneously using the Seldinger technique. A multi-stage venous cannula (25Fr Medtronic Bio-Medicus®, Dublin, Republic of Ireland) was inserted into a femoral vein (for both veno-arterial ECMO and veno-venous ECMO) for drainage of venous blood from the patient. An arterial cannula (19Fr or 21Fr Medtronic Bio-Medicus) , to return blood from the ECMO circuit to the patient, was inserted into a femoral artery for veno-arterial ECMO, or the right internal jugular vein (preferential site) for veno-venous ECMO. In addition, patients on veno-arterial ECMO had a distal perfusion cannula inserted into the ipsilateral femoral artery (8. 
Anticoagulation and measurements
All patients were anticoagulated with UFH infused into a dedicated lumen of a central venous cannula. During cannulation, a bolus of UFH (25 to 100 units/kg) was given. Thereafter, once the ACT fell to below 300 seconds, an infusion of UFH was commenced, and the rate was adjusted to maintain the aPTT within a specified target range. The target aPTT range could be selected by the treating clinician on a daily basis from one of the three options: low range (40 to 60 seconds), medium range (50 to 80 seconds), or high range (60 to 90 seconds), based on the perceived risks of bleeding versus thrombosis. Blood samples were obtained every six hours for aPTT, International Normalized Ratio, fibrinogen, D-dimer, ACT, haemoglobin concentration and platelet count. Thromboelastometry was performed once per day, at the same time as one of the sets of six-hourly tests.
The coagulation tests were performed using a STA-R Evolution® coagulation analyser (Diagnostica Stago, Asnieressur-Seine, France). The ACT was performed at the point-ofcare, using a Hemochron 401® ACT machine (ITC Nexus Dx, Edison, NJ, USA) and low range ACT cartridges, by accredited nurses. For thromboelastometry, whole blood samples were collected in 3.8% sodium citrate tubes and immediately analysed using the INTEM protocol on a ROTEM analyser. The clotting time (CT) of the INTEM test represents time to thrombin generation through the intrinsic pathway and hence the effect of heparin. The clot formation time (CFT) represents the initial rate of fibrin polymerisation. The ROTEM analyser was tested twice weekly for correct function using quality control serum (ROTROL®, Pentapharm GmbH, Munich, Germany). At our laboratory, the reference ranges for aPTT, ACT and INTEM CT are 24 to 38 seconds, 70 to 170 seconds and 100 to 240 seconds 20 , respectively.
Data were collected on patient demographics, severity of illness, indication, type and duration of ECMO, and patient outcome. Total number of documented bleeding and clotting episodes were also recorded. Data points, defined as instances in time during ECMO when INTEM CT, aPTT and ACT were performed simultaneously, were included in the study. The person collecting data was not aware of the objectives of the study.
Statistical analysis
Both descriptive and inferential statistics were used. The data is presented as median with interquartile range and proportions. Correlation was assessed using Spearman's rho (r s ). Categorical variables were assessed using contingency table and chi-square test. Medians across different groups were compared using Kruskal-Wallis, with post hoc analysis using Dunn-Bonferroni test. Receiver operating curve analysis was used to assess predictive values of test cut-offs. Statistical analysis was performed using SPSS version 21.0 (Armonk, NY, USA). For all tests, a two-sided P-value of less than 0.05 was considered significant.
Results
During the study period, 20 patients received ECMO for a total of 203 days. Patient demographic and ECMO treatment variables are shown in Table 1 . The three most common indications for ECMO were acute respiratory distress syndrome (5; 25%), cardiogenic shock accompanying non-ischaemic cardiomyopathy (4; 20%), and perioperative valvular heart surgery (4; 20%). The median turnaround time was shortest for ACT at six (six to seven) minutes, followed by ROTEM 16 (14 to 19) minutes and aPTT 48 (44 to 60) minutes. Two hundred data points were available for analysis.
Heparin infusion rates and aPTT results
Of the 200 data points, the aPTT target range for UFH infusion was low in 30 (15%), medium in 74 (37%) and high in 96 (48%) data points. The UFH was being infused during 184 (92%) out of 200 data points. The overall median UFH infusion rate was 12.4 (9.0 to 16.8) units(U)/kg/hour. The median UFH infusion rate was 6.8 (0 to 12.8) U/kg/hour, 11.2 (9.6 to 15) U/ kg/hour, and 14.8 (10 to 17.2) U/ kg/hour within low, medium and high aPTT target range data points, respectively. The aPTT was subtherapeutic, therapeutic and supratherapeutic in eight (26.7%), 17 (56.7%) and five (16.7%) data points, respectively, when low aPTT range was being targeted; 10 (13.5%), 52 (70.3%) and 12 (16.2%) data points, respectively, when medium aPTT range was being targeted; and 12 (12.5%), 63 (65.2%) and 21 (21.9%) data points when high aPTT range was being targeted. The coagulation test results are shown in Table 2 .
Heparin infusion rates and comparison of aPTT, ACT and INTEM CT
During infusion of UFH, all (except one) aPTT and ACT results were elevated above the reference ranges for these tests; but in contrast, only half of the INTEM CT results were elevated above the reference range for normal subjects. On the other hand, in the absence of UFH infusion, only 37% (six) of the aPTT results and 63% (ten) of the ACT results were within the normal reference range; in contrast to 81.3% (13) 
Comparison between aPTT and INTEM CT
There was a poor correlation between aPTT and INTEM CT (r s =0.310, P <0.001, 95% CI [0.17, 0.43]) and no correlation between aPTT and INTEM CFT (r s =-0.06, P=0.4, 95% CI [-0.19,0.08]). Figure 1 illustrates the distribution of INTEM CT results when the concurrent aPTT results were below, within or above the target aPTT range (for each of low, medium and high aPTT target ranges). The association between aPTT and INTEM 
Comparison between aPTT and ACT
There was a moderate correlation between ACT and aPTT (r s =0.40, P <0.001, 95% CI [0.28,0.51]) and between ACT and INTEM CT (r s =0.395, P <0.001, 95% CI [0.27,0.50]). The association between ACT and aPTT values was best when the aPTT target range was low (r s =0.78, P <0.001, 95% CI [0.58,0.89]), followed by medium (r s =0.42, P <0.001, 95% CI [0.21,0.59]) and high (r s =0.24, P=0.02, 95% CI [0.04, 0.42]) aPTT target ranges. However, 70% of ACT values were less than 170 seconds against only 26.7% of subtherapeutic aPTT, when low aPTT range was being targeted. 
Haemorrhagic and thrombotic complications

Discussion
This study found a weak correlation between concurrently taken INTEM CT and aPTT results in the setting of ECMO therapy with UFH anticoagulation. The INTEM CT was less sensitive than aPTT to UFH therapy or other derangement of haemostatic function. Neither INTEM® CT, nor ACT provided equivalent results to aPTT for guiding adjustment of the UFH infusion rate during ECMO.
The aPTT assay measures the time to fibrin clot formation of plasma via the intrinsic and common pathways of coagulation in vitro 21 . A citrated plasma sample is incubated with phospholipid, micronised silica (surface activator) and 0.02% sodium azide (preservative). Then calcium is added and the time to a change in optical transmittance measured 21 . In our study, some degree of discordance between aPTT and heparin activity is likely to have been present, and this has been previously reported in a study of paediatric ECMO using chromogenic anti-factor Xa assay 22 . Neither the aPTT test, nor anti-factor Xa activity have a strong evidence base for predicting the safety and efficacy of UFH therapy 23 , although aPTT has been shown to be superior to ACT-guided heparin management for ECMO 24 . Since aPTT is performed on plasma, it does not account for platelet or endothelial function and hence, may provide an incomplete measure of risk of thrombosis or haemorrhage accompanying complex coagulopathy in patients on prolonged ECMO. It would be ideal to have a single test that could provide both a guide to heparin dosing and a global assessment of haemostatic function.
The ACT evaluates the time to fibrin clot formation of fresh whole blood. Coagulation is activated by kaolin suspended in buffer and is detected by a photo optical sensor. Although widely used to monitor the anticoagulant effect of heparin in cardiopulmonary bypass, the ACT is less sensitive to the anticoagulant effect of heparin at the lower doses used with ECMO in the intensive care setting 1, 8, 22 . Despite this limitation, the previous lack of a suitable alternative point-of-care test has made the ACT the monitoring tool of choice in most paediatric ECMO centres 2, 3 . Several studies have demonstrated that ACT correlates poorly with anti-factor Xa activity during ECMO 3, 22 , and that aPTT monitoring may be superior 24 . However, the aPTT may be significantly prolonged due to haemodilution, especially in paediatric patients, even in the absence of heparin therapy 1,2 . This raises uncertainty in interpretation of aPTT results, and is another reason why many paediatric ECMO centres favour ACT monitoring. Consistent with previous studies in multiple clinical settings including ECMO, we found a poor correlation between ACT and aPTT 24 . We have extended this finding to demonstrate that in determining whether to increase, decrease or not change the UFH infusion rate, the ACT corresponded poorly with aPTT, especially for higher aPTT target ranges (Figure 1 ).
The INTEM CT involves activation of coagulation of a sample of citrated whole blood by the addition of ellagic acid, phospholipid (partial thromboplastin) and calcium, and viscoelastometry is used to determine the time to clot formation. Previous experience with ROTEM comes principally from the management of bleeding in the setting of major trauma 25 , sepsis 18 , post-cardiac surgery 26 and liver transplantation 27 . Previous studies have shown conflicting reports of a correlation between INTEM CT and aPTT 28 .
Although advocated in recent Extracorporeal Life Support Organization anticoagulation guidelines 2 , ROTEM, and more specifically the INTEM assay, have not been evaluated as a guide to UFH dose adjustment during ECMO. In our study there was a weak correlation between INTEM CT and aPTT, with the two tests likely to lead to differences in heparin dose adjustment in practice. Our finding of prolongation of aPTT without INTEM CT prolongation has been reported previously in a study of paediatric surgical patients 28 and patients on ECMO 19 .
There are a number of potential explanations for the limited concordance seen between INTEM CT and aPTT. Both use citrated samples and use similar reagents, but have differences in contact activation, the concentration of reagents and the method of fibrin clot detection. The biggest difference between the two tests is that the former is performed on a sample of whole blood and the latter on plasma. Plasma-based tests do not assess the cellular aspects of coagulation and are more profoundly affected by haemodilution, a common feature during ECMO [1] [2] [3] . It has been hypothesised that, whereas the aPTT is prolonged by haemodilution due to the direct dilution of coagulation factors, platelet activation overcomes this effect with whole blood-based tests such as ROTEM and ACT 29 . However, marked qualitative platelet dysfunction was recently demonstrated in patients on ECMO 19 . Besides haemodilution, other iatrogenic coagulopathy such as acquired Von Willebrand disease 19, 30, 31 in these patients may affect aPTT more than ROTEM. Also, the normal INTEM CT values were defined using the manufacturer's recommended reference range, which has been established based on a healthy adult population.
There is a lack of clinical validity for this reference range in ECMO patients. The ROC analysis in our study revealed that the INTEM CT value that predicted a deranged aPTT result was 189 seconds. Although this analysis was undermined by poor correlation, the result does suggest lower reference ranges for INTEM CT in ECMO patients as compared to healthy adults. There was no correlation between INTEM CFT and aPTT. Two previous studies have shown better correlation between CFT and aPTT than CT and aPTT. Both studies assessed native clotting alterations, unlike our study in which ROTEM was performed in the presence of significant doses of anticoagulant. Whether the behaviour of the test differs when used to detect native coagulation disturbances versus anticoagulant-induced disturbances is not clear.
The potential advantages of ROTEM make it an attractive option for monitoring the coagulation status of patients on ECMO. However, there are also a number of disadvantages to ROTEM. Firstly, in our study population a significant proportion of INTEM CT results during heparin therapy were within the normal reference range, which questions the sensitivity of INTEM CT to heparin effect. Furthermore, this suggests that if heparin titration was based solely on achieving INTEM CT results above normal range, it is likely that significantly higher rates of heparin would be infused. Given the lack of thrombotic complications and high incidence of bleeding in our cohort, this finding is concerning. The presence of small amounts of thrombus within the oxygenator was a common finding and may represent a surrogate marker of subclinical thrombosis affecting organ function within the patient. Secondly, the cost of a single test (including consumables and labour) was 28% higher for INTEM (A$17.60) than aPTT (A$13.70) and 151% higher than for ACT (A$7.00). Thirdly, ROTEM tests, unlike aPTT, are unable to detect the presence of acquired Von Willebrand factor deficiency, which is a recognised complication of ECMO (and UFH therapy), and may increase the risk of bleeding 19, 30, 31 . Thus the precise role of ROTEM for anticoagulation monitoring and in the management of patients on ECMO requires further study.
Limitations
This study was retrospective in nature, but by including only 'routine' test samples, the validity of assessing correlation and agreement between the tests for guiding heparin titration was ensured. However, this limited our ability to study the association between the different measures of coagulation status and bleeding episodes, transfusion requirements and thrombosis. Also whether bleeding was surgical, anticoagulation-related, or due to underlying coagulopathy can't be interpreted with this retrospective study data. Suitable data points (when aPTT, ACT and INTEM CT samples were taken concurrently) were only available once each day for each patient whereas aPTT samples were taken from patients every six hours to guide heparin titration. Thus, only a snapshot of anticoagulant monitoring was captured. This is unlikely to introduce bias as the hypothesis was focused on agreement between tests and only those test results where the blood samples for the tests were taken simultaneously were studied. Test repeatability and user dependence (for ACT) were not examined. The HEPTEM assay was not performed, limiting our evaluation of the specific effect of heparin on INTEM CT. However, the INTEM CT was affected by heparin as shown by significantly higher INTEM CT values at higher heparin infusion rates, although nearly half of the data points had results within normal limits despite UFH exposure and elevated aPTT. Our study also did not evaluate other measurements obtained from ROTEM tests, other coagulation tests, or factors affecting coagulation, as this was not the purpose of this study. We have compared the INTEM CT with currently used tests such as aPTT, which are themselves profoundly affected by various disturbances in coagulation induced by the extracorporeal circuit. The lack of gold standard hinders the explanation of the study results. However, the currently used tests of aPTT and ACT are the standard of practice 3 and the comparison still allows us to analyse the hypothesis.
Conclusion
Our results demonstrated that aPTT, and INTEM CT using the manufacturer's recommended reference range, do not provide equivalent information to guide UFH infusion rate titration during ECMO. Our study suggests caution regarding use of ROTEM for guiding UFH-based anticoagulation as it may lead to excessive UFH exposure. Further studies using a gold standard are required to identify the specific role of ROTEM-based coagulation monitoring in patients on ECMO. Further studies should also evaluate coagulation test results relative to objective measures of bleeding and thrombosis.
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